{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:05:47Z","timestamp":1790867147959,"version":"4.1.0"},"reference-count":181,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00228-024-03749-8","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T07:02:02Z","timestamp":1725606122000},"page":"1659-1684","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Therapeutic drug monitoring in tuberculosis"],"prefix":"10.1007","volume":"80","author":[{"given":"M.","family":"Sarkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,6]]},"reference":[{"key":"3749_CR1","unstructured":"Global Tuberculosis Report (2023) https:\/\/www.who.int\/publications-detail-redirect\/9789240083851 (Accessed on 6th November, 2023)"},{"key":"3749_CR2","unstructured":"WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment. https:\/\/www.who.int\/publications\/i\/item\/9789240048126 (Accessed on 6th November, 2023)"},{"key":"3749_CR3","unstructured":"Frieden T (2004) What is intermittent treatment and what is the scientific basis for intermittency? In: Frieden T (ed) Toman\u2019s tuberculosis: case detection, treatment, and monitoring\u2014questions and answers, 2nd edn. World Health Organization,\u00a0Geneva, Switzerland, pp 130\u2013138. Publication No. WHO\/HTM\/TB\/2004.334"},{"issue":"1","key":"3749_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190207","volume":"13","author":"BE Feleke","year":"2018","unstructured":"Feleke BE, Alene GD, Feleke TE, Motebaynore Y, Biadglegne F (2018) Clinical response of tuberculosis patients, a prospective cohort study. PLoS ONE 13(1):e0190207. https:\/\/doi.org\/10.1371\/journal.pone.0190207","journal-title":"PLoS ONE"},{"issue":"10","key":"3749_CR5","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.3201\/eid1610.100374","volume":"16","author":"SK Heysell","year":"2010","unstructured":"Heysell SK, Moore JL, Keller SJ, Houpt ER (2010) Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerg Infect Dis 16(10):1546\u20131553. https:\/\/doi.org\/10.3201\/eid1610.100374","journal-title":"Emerg Infect Dis"},{"key":"3749_CR6","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/129723","volume":"2013","author":"SK Heysell","year":"2013","unstructured":"Heysell SK, Moore JL, Staley D, Dodge D, Houpt ER (2013) Early therapeutic drug monitoring for isoniazid and rifampin among diabetics with newly diagnosed tuberculosis in Virginia, USA. Tuberc Res Treat 2013:129723. https:\/\/doi.org\/10.1155\/2013\/129723","journal-title":"Tuberc Res Treat"},{"key":"3749_CR7","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.2165\/00003495-200262150-00001","volume":"62","author":"CA Peloquin","year":"2002","unstructured":"Peloquin CA (2002) Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 62:2169\u20132183. https:\/\/doi.org\/10.2165\/00003495-200262150-00001","journal-title":"Drugs"},{"key":"3749_CR8","unstructured":"Technical report on the pharmacokinetics and pharmacodynamics (PK\/PD) of medicines used in the treatment of drug-resistant tuberculosis. https:\/\/iris.who.int\/bitstream\/handle\/10665\/260440\/WHO-CDS-TB-2018.6-eng.pdf (Accessed on 6th November, 2023)"},{"issue":"1","key":"3749_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/17425255.2021.1836158","volume":"17","author":"AG M\u00e4rtson","year":"2021","unstructured":"M\u00e4rtson AG, Burch G, Ghimire S, Alffenaar JC, Peloquin CA (2021) Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems. Expert Opin Drug Metab Toxicol 17(1):23\u201339. https:\/\/doi.org\/10.1080\/17425255.2021.1836158","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"3749_CR10","doi-asserted-by":"publisher","first-page":"S365","DOI":"10.1093\/cid\/ciy710","volume":"67","author":"D Falzon","year":"2018","unstructured":"Falzon D, Jaramillo E, Gilpin C, Weyer K (2018) The role of novel approaches and new findings in the pharmacology of tuberculosis medicines in improving treatment outcomes. Clin Infect Dis 67:S365\u2013S367. https:\/\/doi.org\/10.1093\/cid\/ciy710","journal-title":"Clin Infect Dis"},{"key":"3749_CR11","doi-asserted-by":"publisher","first-page":"e00636","DOI":"10.1128\/AAC.00636-18","volume":"62","author":"NC Ammerman","year":"2018","unstructured":"Ammerman NC, Swanson RV, Bautista EM, Almeida DV, Saini V, Omansen TF et al (2018) Impact of clofazimine dosing on treatment shortening of the first-line regimen in a mouse model of tuberculosis. Antimicrob Agents Chemother 62:e00636-e718. https:\/\/doi.org\/10.1128\/AAC.00636-18","journal-title":"Antimicrob Agents Chemother"},{"key":"3749_CR12","doi-asserted-by":"publisher","first-page":"4181","DOI":"10.1128\/AAC.00115-15","volume":"59","author":"LE Via","year":"2015","unstructured":"Via LE, England K, Weiner DM, Schimel D, Zimmerman MD, Dayao E et al (2015) A sterilizing tuberculosis treatment regimen is associated with faster clearance of bacteria in cavitary lesions in marmosets. Antimicrob Agents Chemother 59:4181\u20134189. https:\/\/doi.org\/10.1128\/AAC.00115-15","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"3749_CR13","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1183\/09031936.00142614","volume":"45","author":"A Daskapan","year":"2015","unstructured":"Daskapan A, de Lange WC, Akkerman OW, Kosterink JG, van der Werf TS, Stienstra Y, Alffenaar JW (2015) The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection. Eur Respir J 45(2):569\u2013571. https:\/\/doi.org\/10.1183\/09031936.00142614","journal-title":"Eur Respir J"},{"issue":"Suppl 1","key":"3749_CR14","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1093\/cid\/civ426","volume":"61","author":"T Gumbo","year":"2015","unstructured":"Gumbo T, Pasipanodya JG, Nuermberger E, Romero K, Hanna D (2015) Correlations between the hollow fiber model of tuberculosis and therapeutic events in tuberculosis patients: learn and confirm. Clin Infect Dis 61(Suppl 1):S18-24. https:\/\/doi.org\/10.1093\/cid\/civ426","journal-title":"Clin Infect Dis"},{"issue":"9","key":"3749_CR15","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1093\/infdis\/jit352","volume":"208","author":"JG Pasipanodya","year":"2013","unstructured":"Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T (2013) Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 208(9):1464\u20131473. https:\/\/doi.org\/10.1093\/infdis\/jit352","journal-title":"J Infect Dis"},{"key":"3749_CR16","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/0168-9525(90)90174-5","volume":"6","author":"FJ Gonzalez","year":"1990","unstructured":"Gonzalez FJ, Nebert DW (1990) Evolution of the P450 gene superfamily: animal-plant \u2018warfare\u2019, molecular drive and human genetic differences in drug oxidation. Trends Genet 6:182\u2013186. https:\/\/doi.org\/10.1016\/0168-9525(90)90174-5","journal-title":"Trends Genet"},{"key":"3749_CR17","doi-asserted-by":"publisher","first-page":"289","DOI":"10.7326\/0003-4819-127-4-199708150-00006","volume":"127","author":"J Sahai","year":"1997","unstructured":"Sahai J, Gallicano K, Swick L, Tailor S, Garber G, Seguin I et al (1997) Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann Intern Med 127:289\u2013293. https:\/\/doi.org\/10.7326\/0003-4819-127-4-199708150-00006","journal-title":"Ann Intern Med"},{"issue":"15","key":"3749_CR18","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1056\/NEJM199310073291513","volume":"329","author":"CA Peloquin","year":"1993","unstructured":"Peloquin CA, MacPhee AA, Berning SE (1993) Malabsorption of antimycobacterial medications. N Engl J Med 329(15):1122\u20131123. https:\/\/doi.org\/10.1056\/NEJM199310073291513","journal-title":"N Engl J Med"},{"key":"3749_CR19","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJM199212173272514","volume":"327","author":"SE Berning","year":"1992","unstructured":"Berning SE, Huitt GA, Iseman MD, Peloquin CA (1992) Malabsorption of antituberculosis medications by a patient with AIDS. N Engl J Med 327:1817\u20131818. https:\/\/doi.org\/10.1056\/NEJM199212173272514","journal-title":"N Engl J Med"},{"key":"3749_CR20","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1093\/infdis\/168.6.1559","volume":"168","author":"SM Gordon","year":"1993","unstructured":"Gordon SM, Horsburgh CR Jr, Peloquin CA, Havlik JA Jr, Metchock B, Heifets L et al (1993) Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease. J Infect Dis 168:1559\u20131562. https:\/\/doi.org\/10.1093\/infdis\/168.6.1559","journal-title":"J Infect Dis"},{"issue":"7071","key":"3749_CR21","first-page":"1543","volume":"313","author":"MT Barakat","year":"1996","unstructured":"Barakat MT, Scott J, Hughes JM, Walport M, Calam J, Friedland JS et al (1996) Grand Rounds-Hammersmith Hospital. Persistent fever in pulmonary tuberculosis BMJ 313(7071):1543\u20131545","journal-title":"Persistent fever in pulmonary tuberculosis BMJ"},{"issue":"6","key":"3749_CR22","first-page":"421","volume":"43","author":"P Dieterlen","year":"1986","unstructured":"Dieterlen P, Cassereau H, Lestradet H (1986) Malabsorption permanente de la rifampicine chez un diab\u00e9tique atteint d\u2019une maladie coeliaque [Permanent malabsorption of rifampicin in a diabetic with celiac disease]. Arch Fr Pediatr 43(6):421\u2013422","journal-title":"Arch Fr Pediatr"},{"key":"3749_CR23","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1365-2125.1984.tb02377.x","volume":"17","author":"K Polosa","year":"1984","unstructured":"Polosa K, Murphy KJR, Krishnaswamy K (1984) Rifampicin kinetics in undernutrition. Br J Cin Pharmacol 17:481\u2013484. https:\/\/doi.org\/10.1111\/j.1365-2125.1984.tb02377.x","journal-title":"Br J Cin Pharmacol"},{"issue":"7","key":"3749_CR24","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1086\/507543","volume":"43","author":"HM Nijland","year":"2006","unstructured":"Nijland HM, Ruslami R, Stalenhoef JE, Nelwan EJ, Alisjahbana B, Nelwan RH et al (2006) Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis 43(7):848\u2013854. https:\/\/doi.org\/10.1086\/507543","journal-title":"Clin Infect Dis"},{"issue":"6","key":"3749_CR25","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2165\/00003088-199120060-00004","volume":"20","author":"PR Gwilt","year":"1991","unstructured":"Gwilt PR, Nahhas RR, Tracewell WG (1991) The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmaco 20(6):477\u2013490. https:\/\/doi.org\/10.2165\/00003088-199120060-00004","journal-title":"Clin Pharmaco"},{"issue":"10","key":"3749_CR26","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1086\/429321","volume":"40","author":"M Weiner","year":"2005","unstructured":"Weiner M, Benator D, Burman W, Peloquin CA, Khan A, Vernon A et al (2005) Tuberculosis Trials Consortium. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 40(10):1481\u201391. https:\/\/doi.org\/10.1086\/429321","journal-title":"Clin Infect Dis"},{"issue":"5","key":"3749_CR27","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/1545109712454454","volume":"11","author":"R Ahmed","year":"2012","unstructured":"Ahmed R, Cooper R, Foisy M, Der E, Kunimoto D (2012) Factors associated with reduced antituberculous serum drug concentrations in patients with HIV-TB coinfection. J Int Assoc Physicians AIDS Care (Chic) 11(5):273\u2013276. https:\/\/doi.org\/10.1177\/1545109712454454","journal-title":"J Int Assoc Physicians AIDS Care (Chic)"},{"issue":"12","key":"3749_CR28","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1093\/jac\/dkz368","volume":"74","author":"CM Mtabho","year":"2019","unstructured":"Mtabho CM, Semvua HH, van den Boogaard J, Irongo CF, Boeree MJ, Colbers A et al (2019) Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients. J Antimicrob Chemother 74(12):3537\u20133545. https:\/\/doi.org\/10.1093\/jac\/dkz368","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"3749_CR29","doi-asserted-by":"publisher","first-page":"1900373","DOI":"10.1183\/13993003.00373-2019","volume":"54","author":"BGJ Dekkers","year":"2019","unstructured":"Dekkers BGJ, Bolhuis MS, Ter Beek L, de Lange WCM, van der Werf TS, Alffenaar JC, Akkerman OW (2019) Reduced moxifloxacin exposure in patients with tuberculosis and diabetes. Eur Respir J 54(3):1900373. https:\/\/doi.org\/10.1183\/13993003.00373-2019","journal-title":"Eur Respir J"},{"issue":"4","key":"3749_CR30","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.2337\/db14-0228","volume":"64","author":"A Abbasi","year":"2015","unstructured":"Abbasi A, Deetman PE, Corpeleijn E, Gansevoort RT, Gans RO, Hillege HL et al (2015) Bilirubin as a potential causal factor in type 2 diabetes risk: a Mendelian randomization study. Diabetes 64(4):1459\u20131469. https:\/\/doi.org\/10.2337\/db14-0228","journal-title":"Diabetes"},{"issue":"1","key":"3749_CR31","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12879-017-2226-y","volume":"17","author":"Y Alkabab","year":"2017","unstructured":"Alkabab Y, Keller S, Dodge D, Houpt E, Staley D, Heysell S (2017) Early interventions for diabetes related tuberculosis associate with hastened sputum microbiological clearance in Virginia, USA. BMC Infect Dis 17(1):125. https:\/\/doi.org\/10.1186\/s12879-017-2226-y","journal-title":"BMC Infect Dis"},{"key":"3749_CR32","doi-asserted-by":"publisher","first-page":"511","DOI":"10.2165\/00003088-198409060-00003","volume":"9","author":"MR Holdiness","year":"1984","unstructured":"Holdiness MR (1984) Clinical pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet 9:511\u2013544. https:\/\/doi.org\/10.2165\/00003088-198409060-00003","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"3749_CR33","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1086\/431984","volume":"41","author":"JW Tappero","year":"2005","unstructured":"Tappero JW, Bradford WZ, Agerton TB, Hopewell P, Reingold AL, Lockman S et al (2005) Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin Infect Dis 41(4):461\u2013469. https:\/\/doi.org\/10.1086\/431984","journal-title":"Clin Infect Dis"},{"issue":"4","key":"3749_CR34","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1128\/AAC.50.4.1170-1177.2006","volume":"50","author":"H McIlleron","year":"2006","unstructured":"McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P (2006) Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother 50(4):1170\u20131177. https:\/\/doi.org\/10.1128\/AAC.50.4.1170-1177.2006","journal-title":"Antimicrob Agents Chemother"},{"key":"3749_CR35","unstructured":"Peloquin CA (1991) Antituberculosis drugs: pharmacokinetics. In: Heifets L, editor. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton: CRC Press; 1991: 59\u201388"},{"issue":"7","key":"3749_CR36","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1093\/cid\/ciw376","volume":"63","author":"P Nahid","year":"2016","unstructured":"Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A et al (2016) Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis 63(7):e147\u2013e195. https:\/\/doi.org\/10.1093\/cid\/ciw376","journal-title":"Clin Infect Dis"},{"issue":"1","key":"3749_CR37","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jceh.2012.12.001","volume":"3","author":"V Ramappa","year":"2013","unstructured":"Ramappa V, Aithal GP (2013) Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. J Clin Exp Hepatol 3(1):37\u201349. https:\/\/doi.org\/10.1016\/j.jceh.2012.12.001","journal-title":"J Clin Exp Hepatol"},{"issue":"2","key":"3749_CR38","doi-asserted-by":"publisher","first-page":"188","DOI":"10.5588\/ijtld.13.0128","volume":"18","author":"A Satyaraddi","year":"2014","unstructured":"Satyaraddi A, Velpandian T, Sharma SK, Vishnubhatla S, Sharma A, Sirohiwal A et al (2014) Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity. Int J Tuberc Lung Dis 18(2):188\u201395, i\u2212iii. https:\/\/doi.org\/10.5588\/ijtld.13.0128","journal-title":"Int J Tuberc Lung Dis"},{"issue":"10","key":"3749_CR39","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1164\/rccm.201909-1874ST","volume":"200","author":"P Nahid","year":"2019","unstructured":"Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL et al (2019) Treatment of drug-resistant tuberculosis. An official ATS\/CDC\/ERS\/IDSA clinical practice guideline. Am J Respir Crit Care Med 200(10):e93\u2013e142. https:\/\/doi.org\/10.1164\/rccm.201909-1874ST","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"3749_CR40","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1128\/AAC.01474-09","volume":"54","author":"T Gumbo","year":"2010","unstructured":"Gumbo T (2010) New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic\/pharmacodynamic science and population pharmacokinetic variability. Antimicrob Agents Chemother 54(4):1484\u20131491. https:\/\/doi.org\/10.1128\/AAC.01474-09","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"3749_CR41","doi-asserted-by":"publisher","first-page":"530","DOI":"10.4103\/ijmr.IJMR_552_15","volume":"145","author":"AKH Kumar","year":"2017","unstructured":"Kumar AKH, Chandrasekaran V, Kumar AK, Kawaskar M, Lavanya J, Swaminathan S, Ramachandran G (2017) Food significantly reduces plasma concentrations of first-line anti-tuberculosis drugs. Indian J Med Res 145(4):530\u2013535. https:\/\/doi.org\/10.4103\/ijmr.IJMR_552_15","journal-title":"Indian J Med Res"},{"issue":"8","key":"3749_CR42","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1128\/AAC.00756-15","volume":"59","author":"MG Sturkenboom","year":"2015","unstructured":"Sturkenboom MG, Mulder LW, de Jager A, van Altena R, Aarnoutse RE, de Lange WC et al (2015) Pharmacokinetic modeling and optimal sampling strategies for therapeutic drug monitoring of rifampin in patients with tuberculosis. Antimicrob Agents Chemother 59(8):4907\u20134913. https:\/\/doi.org\/10.1128\/AAC.00756-15","journal-title":"Antimicrob Agents Chemother"},{"key":"3749_CR43","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s10096-004-1109-5","volume":"23","author":"E Nuermberger","year":"2004","unstructured":"Nuermberger E, Grosset J (2004) Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur J Clin Microbiol Infect Dis 23:243\u2013255. https:\/\/doi.org\/10.1007\/s10096-004-1109-5","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"8","key":"3749_CR44","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s00228-016-2083-4","volume":"72","author":"RK Verbeeck","year":"2016","unstructured":"Verbeeck RK, G\u00fcnther G, Kibuule D, Hunter C, Rennie TW (2016) Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring. Eur J Clin Pharmacol 72(8):905\u2013916. https:\/\/doi.org\/10.1007\/s00228-016-2083-4","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"3749_CR45","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1093\/jac\/dky152","volume":"73","author":"KE Stott","year":"2018","unstructured":"Stott KE, Pertinez H, Sturkenboom MGG, Boeree MJ, Aarnoutse R, Ramachandran G et al (2018) Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis. J Antimicrob Chemother 73(9):2305\u20132313. https:\/\/doi.org\/10.1093\/jac\/dky152","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"3749_CR46","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1093\/jac\/dkp262","volume":"64","author":"T Sch\u00f6n","year":"2009","unstructured":"Sch\u00f6n T, Jur\u00e9en P, Giske CG, Chryssanthou E, Stureg\u00e5rd E, Werngren J et al (2009) Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis. J Antimicrob Chemother 64(4):786\u2013793. https:\/\/doi.org\/10.1093\/jac\/dkp262","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"3749_CR47","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1128\/AAC.01830-15","volume":"60","author":"MT Chirehwa","year":"2015","unstructured":"Chirehwa MT, Rustomjee R, Mthiyane T, Onyebujoh P, Smith P, McIlleron H et al (2015) Model-based evaluation of higher doses of rifampin using a semimechanistic model incorporating autoinduction and saturation of hepatic extraction. Antimicrob Agents Chemother 60(1):487\u2013494. https:\/\/doi.org\/10.1128\/AAC.01830-15","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"3749_CR48","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1128\/AAC.01533-06","volume":"51","author":"T Gumbo","year":"2007","unstructured":"Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, Salfinger M et al (2007) Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 51(11):3781\u20133788. https:\/\/doi.org\/10.1128\/AAC.01533-06","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"3749_CR49","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1128\/AAC.47.7.2118-2124.2003","volume":"47","author":"R Jayaram","year":"2003","unstructured":"Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R et al (2003) Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 47(7):2118\u20132124. https:\/\/doi.org\/10.1128\/AAC.47.7.2118-2124.2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"3749_CR50","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2165\/00003088-199937020-00003","volume":"37","author":"JG Douglas","year":"1999","unstructured":"Douglas JG, McLeod MJ (1999) Pharmacokinetic factors in the modern drug treatment of tuberculosis. Clin Pharmacokinet 37(2):127\u2013146. https:\/\/doi.org\/10.2165\/00003088-199937020-00003","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"3749_CR51","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1080\/17425255.2019.1648432","volume":"15","author":"C Sekaggya-Wiltshire","year":"2019","unstructured":"Sekaggya-Wiltshire C, Dooley KE (2019) Pharmacokinetic and pharmacodynamic considerations of rifamycin antibiotics for the treatment of tuberculosis. Expert Opin Drug Metab Toxicol 15(8):615\u2013618. https:\/\/doi.org\/10.1080\/17425255.2019.1648432","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"3749_CR52","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2165\/00003495-199447060-00008","volume":"47","author":"RN Brogden","year":"1994","unstructured":"Brogden RN, Fitton A (1994) Rifabutin Drugs 47(6):983\u20131009. https:\/\/doi.org\/10.2165\/00003495-199447060-00008","journal-title":"Rifabutin Drugs"},{"issue":"8","key":"3749_CR53","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","volume":"74","author":"A Alsultan","year":"2014","unstructured":"Alsultan A, Peloquin CA (2014) Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 74(8):839\u2013854. https:\/\/doi.org\/10.1007\/s40265-014-0222-8","journal-title":"Drugs"},{"issue":"4","key":"3749_CR54","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2165\/00003495-199856040-00008","volume":"56","author":"B Jarvis","year":"1998","unstructured":"Jarvis B, Lamb HM (1998) Rifapentine. Drugs 56(4):607\u2013616. https:\/\/doi.org\/10.2165\/00003495-199856040-00008","journal-title":"Drugs"},{"issue":"2","key":"3749_CR55","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/cpt.634","volume":"102","author":"RM Savic","year":"2017","unstructured":"Savic RM, Weiner M, MacKenzie WR, Engle M, Whitworth WC, Johnson JL et al (2017) Tuberculosis trials consortium of the centers for disease control and prevention. Defining the optimal dose of rifapentine for pulmonary tuberculosis: exposure-response relations from two phase II clinical trials. Clin Pharmacol Ther 102(2):321\u2013331. https:\/\/doi.org\/10.1002\/cpt.634","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"3749_CR56","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1086\/651377","volume":"201","author":"S Srivastava","year":"2010","unstructured":"Srivastava S, Musuka S, Sherman C, Meek C, Leff R, Gumbo T (2010) Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J Infect Dis 201(8):1225\u20131231. https:\/\/doi.org\/10.1086\/651377","journal-title":"J Infect Dis"},{"issue":"8","key":"3749_CR57","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1093\/cid\/ciz942","volume":"70","author":"JC Alffenaar","year":"2020","unstructured":"Alffenaar JC, Gumbo T, Dooley KE, Peloquin CA, Mcilleron H, Zagorski A, Cirillo DM, Heysell SK, Silva DR, Migliori GB (2020Apr 10) Integrating pharmacokinetics and pharmacodynamics in operational research to end tuberculosis. Clin Infect Dis 70(8):1774\u20131780. https:\/\/doi.org\/10.1093\/cid\/ciz942","journal-title":"Clin Infect Dis"},{"issue":"8","key":"3749_CR58","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1128\/AAC.01681-08","volume":"53","author":"T Gumbo","year":"2009","unstructured":"Gumbo T, Dona CS, Meek C, Leff R (2009) Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother 53(8):3197\u20133204. https:\/\/doi.org\/10.1128\/AAC.01681-08","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"3749_CR59","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1128\/AAC.32.7.1002","volume":"32","author":"M Salfinger","year":"1988","unstructured":"Salfinger M, Heifets LB (1988) Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method. Antimicrob Agents Chemother 32(7):1002\u20131004. https:\/\/doi.org\/10.1128\/AAC.32.7.1002","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"3749_CR60","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/BF00558302","volume":"36","author":"C Lacroix","year":"1989","unstructured":"Lacroix C, Hoang TP, Nouveau J, Guyonnaud C, Laine G, Duwoos H et al (1989) Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects. Eur J Clin Pharmacol 36(4):395\u2013400. https:\/\/doi.org\/10.1007\/BF00558302","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"3749_CR61","doi-asserted-by":"publisher","first-page":"e02625","DOI":"10.1128\/AAC.02625-16","volume":"61","author":"A Alsultan","year":"2017","unstructured":"Alsultan A, Savic R, Dooley KE, Weiner M, Whitworth W, Mac Kenzie WR et al (2017) Tuberculosis Trials Consortium. Population pharmacokinetics of pyrazinamide in patients with tuberculosis. Antimicrob Agents Chemother 61(6):e02625-16. https:\/\/doi.org\/10.1128\/AAC.02625-16","journal-title":"Antimicrob Agents Chemother"},{"key":"3749_CR62","doi-asserted-by":"publisher","first-page":"1032674","DOI":"10.3389\/fphar.2022.1032674","volume":"13","author":"H Zhang","year":"2023","unstructured":"Zhang H, He Y, Davies Forsman L, Paues J, Werngren J, Niward K et al (2023) Population pharmacokinetics and dose evaluations of linezolid in the treatment of multidrug-resistant tuberculosis. Front Pharmacol 13:1032674. https:\/\/doi.org\/10.3389\/fphar.2022.1032674","journal-title":"Front Pharmacol"},{"issue":"13","key":"3749_CR63","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.2165\/00003088-200342130-00004","volume":"42","author":"DJ Stalker","year":"2003","unstructured":"Stalker DJ, Jungbluth GL (2003) Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 42(13):1129\u20131140. https:\/\/doi.org\/10.2165\/00003088-200342130-00004","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"3749_CR64","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/jac\/dky414","volume":"74","author":"I Wainmayer","year":"2019","unstructured":"Wainmayer I, Simboli N, Del Granado M, Palomino JC, Ritacco V, Martin A (2019) Bedaquiline and linezolid MIC distributions and epidemiological cut-off values for Mycobacterium tuberculosis in the Latin American region. J Antimicrob Chemother 74(2):373\u2013379. https:\/\/doi.org\/10.1093\/jac\/dky414","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"3749_CR65","doi-asserted-by":"publisher","first-page":"e00751","DOI":"10.1128\/AAC.00751-17","volume":"61","author":"S Srivastava","year":"2017","unstructured":"Srivastava S, Magombedze G, Koeuth T, Sherman C, Pasipanodya JG, Raj P et al (2017) Linezolid dose that maximizes sterilizing effect while minimizing toxicity and resistance emergence for tuberculosis. Antimicrob Agents Chemother 61(8):e00751-e817. https:\/\/doi.org\/10.1128\/AAC.00751-17","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl_3","key":"3749_CR66","doi-asserted-by":"publisher","first-page":"S327","DOI":"10.1093\/cid\/ciy625","volume":"67","author":"MS Bolhuis","year":"2018","unstructured":"Bolhuis MS, Akkerman OW, Sturkenboom MGG, Ghimire S, Srivastava S, Gumbo T et al (2018) Linezolid-based regimens for multidrug-resistant tuberculosis (TB): a systematic review to establish or revise the current recommended dose for TB treatment. Clin Infect Dis 67(suppl_3):S327\u2013S335. https:\/\/doi.org\/10.1093\/cid\/ciy625","journal-title":"Clin Infect Dis"},{"issue":"4","key":"3749_CR67","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1358\/dot.2000.36.4.570201","volume":"36","author":"PA Moise","year":"2000","unstructured":"Moise PA, Birmingham MC, Schentag JJ (2000) Pharmacokinetics and metabolism of moxifloxacin. Drugs Today (Barc) 36(4):229\u2013244. https:\/\/doi.org\/10.1358\/dot.2000.36.4.570201","journal-title":"Drugs Today (Barc)"},{"issue":"9","key":"3749_CR68","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1086\/424849","volume":"190","author":"T Gumbo","year":"2004","unstructured":"Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL (2004) Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 190(9):1642\u20131651. https:\/\/doi.org\/10.1086\/424849","journal-title":"J Infect Dis"},{"issue":"3","key":"3749_CR69","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ijantimicag.2018.10.012","volume":"53","author":"MT Heinrichs","year":"2019","unstructured":"Heinrichs MT, Drusano GL, Brown DL, Maynard MS, Sy SKB, Rand KH (2019) Dose optimization of moxifloxacin and linezolid against tuberculosis using mathematical modeling and simulation. Int J Antimicrob Agents 53(3):275\u2013283. https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.10.012","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"3749_CR70","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1128\/AAC.41.10.2196","volume":"41","author":"LJ Lee","year":"1997","unstructured":"Lee LJ, Hafkin B, Lee ID, Hoh J, Dix R (1997) Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects. Antimicrob Agents Chemother 41(10):2196\u20132200. https:\/\/doi.org\/10.1128\/AAC.41.10.2196","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"3749_CR71","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2165\/00003088-199732020-00002","volume":"32","author":"DN Fish","year":"1997","unstructured":"Fish DN, Chow A (1997) The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 32(2):101\u2013119. https:\/\/doi.org\/10.2165\/00003088-199732020-00002","journal-title":"Clin Pharmacokinet"},{"issue":"suppl_3","key":"3749_CR72","doi-asserted-by":"publisher","first-page":"S293","DOI":"10.1093\/cid\/ciy611","volume":"67","author":"D Deshpande","year":"2018","unstructured":"Deshpande D, Pasipanodya JG, Mpagama SG, Bendet P, Srivastava S, Koeuth T et al (2018) Levofloxacin pharmacokinetics\/pharmacodynamics, dosing, susceptibility breakpoints, and artificial intelligence in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 67(suppl_3):S293\u2013S302. https:\/\/doi.org\/10.1093\/cid\/ciy611","journal-title":"Clin Infect Dis"},{"issue":"5","key":"3749_CR73","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3109\/00365549009027099","volume":"22","author":"R Maller","year":"1990","unstructured":"Maller R, Emanuelsson BM, Isaksson B, Nilsson L (1990) Amikacin once daily: a new dosing regimen based on drug pharmacokinetics. Scand J Infect Dis 22(5):575\u2013579. https:\/\/doi.org\/10.3109\/00365549009027099","journal-title":"Scand J Infect Dis"},{"issue":"3","key":"3749_CR74","doi-asserted-by":"publisher","first-page":"e01724","DOI":"10.1128\/AAC.01724-17","volume":"62","author":"JA Dijkstra","year":"2018","unstructured":"Dijkstra JA, van der Laan T, Akkerman OW, Bolhuis MS, de Lange WCM, Kosterink JGW et al (2018) In Vitro susceptibility of mycobacterium tuberculosis to amikacin, kanamycin, and capreomycin. Antimicrob Agents Chemother 62(3):e01724-e1817. https:\/\/doi.org\/10.1128\/AAC.01724-17","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl_3","key":"3749_CR75","doi-asserted-by":"publisher","first-page":"S303","DOI":"10.1093\/cid\/ciy613","volume":"67","author":"MGG Sturkenboom","year":"2018","unstructured":"Sturkenboom MGG, Simbar N, Akkerman OW, Ghimire S, Bolhuis MS, Alffenaar JWC (2018) Amikacin dosing for MDR tuberculosis: a systematic review to establish or revise the current recommended dose for tuberculosis treatment. Clin Infect Dis 67(suppl_3):S303\u2013S307. https:\/\/doi.org\/10.1093\/cid\/ciy613","journal-title":"Clin Infect Dis"},{"key":"3749_CR76","unstructured":"FDA. 2012.\u00a0Anti-infective drugs advisory committee meeting: briefing document. TMC207 (bedaquiline) treatment of patients with MDR-TB: NDA 204\u2013384. FDA, Silver Spring, MD:\u00a0http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Anti-InfectiveDrugsAdvisoryCommittee\/UCM329260.pdf"},{"issue":"9","key":"3749_CR77","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1093\/jac\/dku171","volume":"69","author":"RP van Heeswijk","year":"2014","unstructured":"van Heeswijk RP, Dannemann B, Hoetelmans RM (2014) Bedaquiline: a review of human pharmacokinetics and drug-drug interactions. J Antimicrob Chemother 69(9):2310\u20132318. https:\/\/doi.org\/10.1093\/jac\/dku171","journal-title":"J Antimicrob Chemother"},{"key":"3749_CR78","doi-asserted-by":"publisher","first-page":"1022090","DOI":"10.3389\/fphar.2023.1022090","volume":"14","author":"G Shao","year":"2023","unstructured":"Shao G, Bao Z, Davies Forsman L, Paues J, Werngren J, Niward K et al (2023) Population pharmacokinetics and model-based dosing evaluation of bedaquiline in multidrug-resistant tuberculosis patients. Front Pharmacol 14:1022090. https:\/\/doi.org\/10.3389\/fphar.2023.1022090","journal-title":"Front Pharmacol"},{"key":"3749_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jctube.2024.100444","volume":"36","author":"NF Maranchick","year":"2024","unstructured":"Maranchick NF, Peloquin CA (2024) Role of therapeutic drug monitoring in the treatment of multi-drug resistant tuberculosis. J Clin Tuberc Other Mycobact Dis 36:100444. https:\/\/doi.org\/10.1016\/j.jctube.2024.100444","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"issue":"9","key":"3749_CR80","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1128\/AAC.00106-09","volume":"53","author":"AM Ginsberg","year":"2009","unstructured":"Ginsberg AM, Laurenzi MW, Rouse DJ, Whitney KD, Spigelman MK (2009) Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects. Antimicrob Agents Chemother 53(9):3720\u20133725. https:\/\/doi.org\/10.1128\/AAC.00106-09","journal-title":"Antimicrob Agents Chemother"},{"key":"3749_CR81","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.2147\/DDDT.S281639","volume":"15","author":"SL Stancil","year":"2021","unstructured":"Stancil SL, Mirzayev F, Abdel-Rahman SM (2021) Profiling pretomanid as a therapeutic option for TB Infection: evidence to date. Drug Des Devel Ther 15:2815\u20132830. https:\/\/doi.org\/10.2147\/DDDT.S281639","journal-title":"Drug Des Devel Ther"},{"key":"3749_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2022.100128","volume":"3","author":"S Occhineri","year":"2022","unstructured":"Occhineri S, Matucci T, Rindi L, Tiseo G, Falcone M, Riccardi N et al (2022) Pretomanid for tuberculosis treatment: an update for clinical purposes. Curr Res Pharmacol Drug Discov 3:100128. https:\/\/doi.org\/10.1016\/j.crphar.2022.100128","journal-title":"Curr Res Pharmacol Drug Discov"},{"issue":"8","key":"3749_CR83","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1128\/AAC.01354-09","volume":"54","author":"AH Diacon","year":"2010","unstructured":"Diacon AH, Dawson R, Hanekom M, Narunsky K, Maritz SJ, Venter A et al (2010) Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother 54(8):3402\u20133407. https:\/\/doi.org\/10.1128\/AAC.01354-09","journal-title":"Antimicrob Agents Chemother"},{"key":"3749_CR84","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1056\/NEJMoa1112433","volume":"366","author":"MT Gler","year":"2012","unstructured":"Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE et al (2012) Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 366:2151\u20132160. https:\/\/doi.org\/10.1056\/NEJMoa1112433","journal-title":"N Engl J Med"},{"key":"3749_CR85","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2147\/DDDT.S60923","volume":"9","author":"JD Szumowski","year":"2015","unstructured":"Szumowski JD, Lynch JB (2015) Profile of delamanid for the treatment of multidrug-resistant tuberculosis. Drug Des Devel Ther 9:677\u2013682. https:\/\/doi.org\/10.2147\/DDDT.S60923","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"3749_CR86","doi-asserted-by":"publisher","first-page":"e01207","DOI":"10.1128\/AAC.01207-20","volume":"65","author":"S Mallikaarjun","year":"2020","unstructured":"Mallikaarjun S, Chapagain ML, Sasaki T, Hariguchi N, Deshpande D, Srivastava S et al (2020) Cumulative fraction of response for once- and twice-daily delamanid in patients with pulmonary multidrug-resistant tuberculosis. Antimicrob Agents Chemother 65(1):e01207-e1220. https:\/\/doi.org\/10.1128\/AAC.01207-20","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"3749_CR87","doi-asserted-by":"publisher","first-page":"e01905","DOI":"10.1128\/AAC.01905-19","volume":"64","author":"A Faraj","year":"2020","unstructured":"Faraj A, Svensson RJ, Diacon AH, Simonsson USH (2020) Drug effect of clofazimine on persisters explains an unexpected increase in bacterial load in patients. Antimicrob Agents Chemother 64(5):e01905-e1919. https:\/\/doi.org\/10.1128\/AAC.01905-19","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"3749_CR88","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00565-22","volume":"66","author":"S Howlader","year":"2022","unstructured":"Howlader S, Kim MJ, Jony MR, Long NP, Cho YS, Kim DH, Shin JG (2022) Characterization of clofazimine metabolism in human liver microsomal incubation in vitro. Antimicrob Agents Chemother 66(10):e0056522. https:\/\/doi.org\/10.1128\/aac.00565-22","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"3749_CR89","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/jac\/dkaa550","volume":"76","author":"WA Alghamdi","year":"2021","unstructured":"Alghamdi WA, Al-Shaer MH, Kipiani M, Barbakadze K, Mikiashvili L, Kempker RR et al (2021) Pharmacokinetics of bedaquiline, delamanid and clofazimine in patients with multidrug-resistant tuberculosis. J Antimicrob Chemother 76(4):1019\u20131024. https:\/\/doi.org\/10.1093\/jac\/dkaa550","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"3749_CR90","first-page":"1161","volume":"13","author":"HW Lee","year":"2009","unstructured":"Lee HW, Kim DW, Park JH, Kim SD, Lim MS, Phapale PB et al (2009) Pharmacokinetics of prothionamide in patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 13(9):1161\u20131166","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"3749_CR91","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1128\/AAC.45.3.810-814.2001","volume":"45","author":"B Auclair","year":"2001","unstructured":"Auclair B, Nix DE, Adam RD, James GT, Peloquin CA (2001) Pharmacokinetics of ethionamide administered under fasting conditions or with orange juice, food, or antacids. Antimicrob Agents Chemother 45(3):810\u2013814. https:\/\/doi.org\/10.1128\/AAC.45.3.810-814.2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"3749_CR92","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1093\/jac\/dkaa310","volume":"75","author":"MT Abdelwahab","year":"2020","unstructured":"Abdelwahab MT, Wasserman S, Brust JCM, Gandhi NR, Meintjes G, Everitt D et al (2020) Clofazimine pharmacokinetics in patients with TB: dosing implications. J Antimicrob Chemother 1 75(11):3269\u20133277. https:\/\/doi.org\/10.1093\/jac\/dkaa310","journal-title":"J Antimicrob Chemother 1"},{"issue":"10","key":"3749_CR93","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1111\/bcp.14795","volume":"87","author":"P Mugabo","year":"2021","unstructured":"Mugabo P, Mulubwa M (2021) Ethionamide population pharmacokinetics\/pharmacodynamics and therapeutic implications in South African adult patients with drug-resistant tuberculosis. Br J Clin Pharmacol 87(10):3863\u20133870. https:\/\/doi.org\/10.1111\/bcp.14795","journal-title":"Br J Clin Pharmacol"},{"issue":"suppl_3","key":"3749_CR94","doi-asserted-by":"publisher","first-page":"S317","DOI":"10.1093\/cid\/ciy609","volume":"67","author":"D Deshpande","year":"2018","unstructured":"Deshpande D, Pasipanodya JG, Mpagama SG, Srivastava S, Bendet P, Koeuth T et al (2018) Ethionamide pharmacokinetics\/pharmacodynamics-derived dose, the role of MICs in clinical outcome, and the resistance arrow of time in multidrug-resistant tuberculosis. Clin Infect Dis 67(suppl_3):S317\u2013S326. https:\/\/doi.org\/10.1093\/cid\/ciy609","journal-title":"Clin Infect Dis"},{"issue":"8","key":"3749_CR95","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1592\/phco.21.11.891.34524","volume":"21","author":"M Zhu","year":"2001","unstructured":"Zhu M, Nix DE, Adam RD, Childs JM, Peloquin CA (2001) Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids. Pharmacotherapy 21(8):891\u2013897. https:\/\/doi.org\/10.1592\/phco.21.11.891.34524","journal-title":"Pharmacotherapy"},{"issue":"11","key":"3749_CR96","doi-asserted-by":"publisher","first-page":"e01381","DOI":"10.1128\/AAC.01381-20","volume":"64","author":"MT Chirehwa","year":"2020","unstructured":"Chirehwa MT, Court R, de Kock M, Wiesner L, de Vries N, Harding J et al (2020) Population pharmacokinetics of cycloserine and pharmacokinetic\/pharmacodynamic target attainment in multidrug-resistant tuberculosis patients dosed with terizidone. Antimicrob Agents Chemother 64(11):e01381-e1420. https:\/\/doi.org\/10.1128\/AAC.01381-20","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"3749_CR97","doi-asserted-by":"publisher","first-page":"e00055","DOI":"10.1128\/AAC.00055-19","volume":"63","author":"WA Alghamdi","year":"2019","unstructured":"Alghamdi WA, Alsultan A, Al-Shaer MH, An G, Ahmed S, Alkabab Y et al (2019) Cycloserine population pharmacokinetics and pharmacodynamics in patients with tuberculosis. Antimicrob Agents Chemother 63(5):e00055-e119. https:\/\/doi.org\/10.1128\/AAC.00055-19","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"3749_CR98","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s002849900095","volume":"33","author":"N Rastogi","year":"1996","unstructured":"Rastogi N, Labrousse V, Goh KS (1996) In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr Microbiol 33(3):167\u2013175. https:\/\/doi.org\/10.1007\/s002849900095","journal-title":"Curr Microbiol"},{"issue":"3","key":"3749_CR99","doi-asserted-by":"publisher","first-page":"e01824","DOI":"10.1128\/AAC.01824-17","volume":"62","author":"X Yu","year":"2018","unstructured":"Yu X, Zeng X, Shi W, Hu Y, Nie W, Chu N, Huang H (2018) Validation of cycloserine efficacy in treatment of multidrug-resistant and extensively drug-resistant tuberculosis in Beijing. China. Antimicrob Agents Chemother 62(3):e01824-17. https:\/\/doi.org\/10.1128\/AAC.01824-17","journal-title":"China. Antimicrob Agents Chemother"},{"issue":"2","key":"3749_CR100","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116795","volume":"10","author":"SK Heysell","year":"2015","unstructured":"Heysell SK, Ahmed S, Ferdous SS, Khan MS, Rahman SM, Gratz J et al (2015) Quantitative drug-susceptibility in patients treated for multidrug-resistant tuberculosis in Bangladesh: implications for regimen choice. PLoS ONE 10(2):e0116795. https:\/\/doi.org\/10.1371\/journal.pone.0116795","journal-title":"PLoS ONE"},{"issue":"5","key":"3749_CR101","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01700-22","volume":"67","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Zhu L, Davies Forsman L, Paues J, Werngren J, Niward K et al (2023) Population pharmacokinetics and dose evaluation of cycloserine among patients with multidrug-resistant tuberculosis under standardized treatment regimens. Antimicrob Agents Chemother 67(5):e0170022. https:\/\/doi.org\/10.1128\/aac.01700-22","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"3749_CR102","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1473-3099(15)00263-7","volume":"15","author":"PR Donald","year":"2015","unstructured":"Donald PR, Diacon AH (2015) Para-aminosalicylic acid: the return of an old friend. Lancet Infect Dis 15(9):1091\u20131099. https:\/\/doi.org\/10.1016\/S1473-3099(15)00263-7","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"3749_CR103","doi-asserted-by":"publisher","first-page":"6242","DOI":"10.1128\/AAC.03073-14","volume":"58","author":"L de Kock","year":"2014","unstructured":"de Kock L, Sy SK, Rosenkranz B, Diacon AH, Prescott K, Hernandez KR et al (2014) Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis. Antimicrob Agents Chemother 58(10):6242\u20136250. https:\/\/doi.org\/10.1128\/AAC.03073-14","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"3749_CR104","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/j.1875-9114.1994.tb02787.x","volume":"14","author":"CA Peloquin","year":"1994","unstructured":"Peloquin CA, Henshaw TL, Huitt GA, Berning SE, Nitta AT, James GT (1994) Pharmacokinetic evaluation of para-aminosalicylic acid granules. Pharmacotherapy 14(1):40\u201346. https:\/\/doi.org\/10.1002\/j.1875-9114.1994.tb02787.x","journal-title":"Pharmacotherapy"},{"issue":"4","key":"3749_CR105","doi-asserted-by":"publisher","first-page":"1700173","DOI":"10.1183\/13993003.00173-2017","volume":"49","author":"L Davies Forsman","year":"2017","unstructured":"Davies Forsman L, Bruchfeld J, Alffenaar JC (2017) Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis. Eur Respir J 49(4):1700173. https:\/\/doi.org\/10.1183\/13993003.00173-2017","journal-title":"Eur Respir J"},{"issue":"12","key":"3749_CR106","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1093\/infdis\/jir658","volume":"204","author":"S Srivastava","year":"2011","unstructured":"Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T (2011) Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 204(12):1951\u20131959. https:\/\/doi.org\/10.1093\/infdis\/jir658","journal-title":"J Infect Dis"},{"issue":"5","key":"3749_CR107","doi-asserted-by":"publisher","first-page":"601","DOI":"10.5588\/ijtld.13.0268","volume":"18","author":"WY Hung","year":"2014","unstructured":"Hung WY, Yu MC, Chiang YC, Chang JH, Chiang CY, Chang CC et al (2014) Serum concentrations of cycloserine and outcome of multidrug-resistant tuberculosis in Northern Taiwan. Int J Tuberc Lung Dis 18(5):601\u2013606. https:\/\/doi.org\/10.5588\/ijtld.13.0268","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"3749_CR108","doi-asserted-by":"publisher","first-page":"78","DOI":"10.4046\/trd.2015.78.2.78","volume":"78","author":"SK Heysell","year":"2015","unstructured":"Heysell SK, Moore JL, Peloquin CA, Ashkin D, Houpt ER (2015) Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in Virginia, 2009\u20132014. Tuberc Respir Dis (Seoul) 78(2):78\u201384. https:\/\/doi.org\/10.4046\/trd.2015.78.2.78","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"3749_CR109","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/cid\/ciw471","volume":"63","author":"S Swaminathan","year":"2016","unstructured":"Swaminathan S, Pasipanodya JG, Ramachandran G, Hemanth Kumar AK, Srivastava S, Deshpande D et al (2016) Drug concentration thresholds predictive of therapy failure and death in children with tuberculosis: bread crumb trails in random forests. Clin Infect Dis 63:63\u201374. https:\/\/doi.org\/10.1093\/cid\/ciw471","journal-title":"Clin Infect Dis"},{"issue":"5","key":"3749_CR110","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/cid\/ciy179","volume":"67","author":"C Sekaggya-Wiltshire","year":"2018","unstructured":"Sekaggya-Wiltshire C, von Braun A, Lamorde M, Ledergerber B, Buzibye A, Henning L et al (2018) Delayed sputum culture conversion in tuberculosis-human immunodeficiency virus-coinfected patients with low isoniazid and rifampicin concentrations. Clin Infect Dis 67(5):708\u2013716. https:\/\/doi.org\/10.1093\/cid\/ciy179","journal-title":"Clin Infect Dis"},{"issue":"2","key":"3749_CR111","doi-asserted-by":"publisher","first-page":"221","DOI":"10.5588\/ijtld.12.0279","volume":"17","author":"L Van Tongeren","year":"2013","unstructured":"Van Tongeren L, Nolan S, Cook VJ, FitzGerald JM, Johnston JC (2013) Therapeutic drug monitoring in the treatment of tuberculosis: a retrospective analysis. Int J Tuberc Lung Dis 17(2):221\u2013224. https:\/\/doi.org\/10.5588\/ijtld.12.0279","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"3749_CR112","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pupt.2011.12.001","volume":"25","author":"C Magis-Escurra","year":"2012","unstructured":"Magis-Escurra C, van den Boogaard J, Ijdema D, Boeree M, Aarnoutse R (2012) Therapeutic drug monitoring in the treatment of tuberculosis patients. Pulm Pharmacol Ther 25(1):83\u201386. https:\/\/doi.org\/10.1016\/j.pupt.2011.12.001","journal-title":"Pulm Pharmacol Ther"},{"issue":"17","key":"3749_CR113","doi-asserted-by":"publisher","first-page":"30079","DOI":"10.1016\/S2213-2600(17)30079-6","volume":"S2213\u20132600","author":"K Dheda","year":"2017","unstructured":"Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M et al (2017) The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med S2213\u20132600(17):30079\u201330086. https:\/\/doi.org\/10.1016\/S2213-2600(17)30079-6","journal-title":"Lancet Respir Med"},{"key":"3749_CR114","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ijid.2014.12.001","volume":"32","author":"G Sotgiu","year":"2015","unstructured":"Sotgiu G, Alffenaar JW, Centis R, D\u2019Ambrosio L, Spanevello A, Piana A, Migliori GB (2015) Therapeutic drug monitoring: how to improve drug dosage and patient safety in tuberculosis treatment. Int J Infect Dis 32:101\u2013104. https:\/\/doi.org\/10.1016\/j.ijid.2014.12.001","journal-title":"Int J Infect Dis"},{"issue":"1\u20132","key":"3749_CR115","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s0009-8981(01)00646-5","volume":"313","author":"WW Yew","year":"2001","unstructured":"Yew WW (2001) Therapeutic drug monitoring in antituberculosis chemotherapy: clinical perspectives. Clin Chim Acta 313(1\u20132):31\u201336. https:\/\/doi.org\/10.1016\/s0009-8981(01)00646-5","journal-title":"Clin Chim Acta"},{"issue":"4","key":"3749_CR116","doi-asserted-by":"publisher","first-page":"2102787","DOI":"10.1183\/13993003.02787-2021","volume":"59","author":"I Margineanu","year":"2022","unstructured":"Margineanu I, Akkerman O, Cattaneo D, Goletti D, Marriott DJE, Migliori GB et al (2022) Practices of therapeutic drug monitoring in tuberculosis: an international survey. Eur Respir J 59(4):2102787. https:\/\/doi.org\/10.1183\/13993003.02787-2021","journal-title":"Eur Respir J"},{"issue":"2","key":"3749_CR117","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1183\/13993003.01285-2015","volume":"47","author":"EP van der Burgt","year":"2016","unstructured":"van der Burgt EP, Sturkenboom MG, Bolhuis MS, Akkerman OW, Kosterink JG, de Lange WC et al (2016) End TB with precision treatment! Eur Respir J 47(2):680\u2013682. https:\/\/doi.org\/10.1183\/13993003.01285-2015","journal-title":"Eur Respir J"},{"key":"3749_CR118","unstructured":"WHO consolidated guidelines on drug-resistant tuberculosis treatment. https:\/\/www.who.int\/publications-detail-redirect\/9789241550529 (Accessed on 6th November, 2023)"},{"key":"3749_CR119","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jpba.2014.08.026","volume":"102","author":"HJ Kim","year":"2015","unstructured":"Kim HJ, Seo KA, Kim HM, Jeong ES, Ghim JL, Lee SH et al (2015) Simple and accurate quantitative analysis of 20 anti-tuberculosis drugs in human plasma using liquid chromatography-electrospray ionization-tandem mass spectrometry. J Pharm Biomed Anal 102:9\u201316. https:\/\/doi.org\/10.1016\/j.jpba.2014.08.026","journal-title":"J Pharm Biomed Anal"},{"key":"3749_CR120","unstructured":"https:\/\/www.currytbcenter.ucsf.edu\/products\/page\/chapter-3-laboratory (Accessed on 02\/02\/2024)"},{"issue":"3","key":"3749_CR121","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1128\/AAC.43.3.568","volume":"43","author":"CA Peloquin","year":"1999","unstructured":"Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, Childs JM, Nix DE (1999) Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents Chemother 43(3):568\u2013572. https:\/\/doi.org\/10.1128\/AAC.43.3.568","journal-title":"Antimicrob Agents Chemother"},{"key":"3749_CR122","unstructured":"Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis https:\/\/www.who.int\/publications\/i\/item\/9789241548809"},{"key":"3749_CR123","unstructured":"Virginia Department of Health Recommendations and Procedures for the use of Therapeutic Drug Monitoring (TDM). https:\/\/www.vdh.virginia.gov\/content\/uploads\/sites\/175\/2020\/05\/TDM-May-2020.pdf (Accessed on 6th November, 2023)"},{"issue":"2&3","key":"3749_CR124","doi-asserted-by":"publisher","first-page":"211","DOI":"10.4103\/ijmr.IJMR_1835_19","volume":"157","author":"G Ramachandran","year":"2023","unstructured":"Ramachandran G, Hemanth Kumar AK, Kannan T, Thangakunam B, Shankar D, Christopher DJ (2023) Pharmacokinetics of rifampicin, isoniazid & pyrazinamide during daily & intermittent dosing: a preliminary study. Indian J Med Res 157(2&3):211\u2013215. https:\/\/doi.org\/10.4103\/ijmr.IJMR_1835_19","journal-title":"Indian J Med Res"},{"key":"3749_CR125","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.ijid.2020.01.041","volume":"92S","author":"JC Alffenaar","year":"2020","unstructured":"Alffenaar JC, Akkerman OW, Kim HY, Tiberi S, Migliori GB (2020) Precision and personalized medicine and anti-TB treatment: Is TDM feasible for programmatic use? Int J Infect Dis 92S:S5\u2013S9. https:\/\/doi.org\/10.1016\/j.ijid.2020.01.041","journal-title":"Int J Infect Dis"},{"issue":"27","key":"3749_CR126","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.2174\/138161211797470174","volume":"17","author":"DH Vu","year":"2011","unstructured":"Vu DH, Alffenaar JW, Edelbroek PM, Brouwers JR, Uges DR (2011) Dried blood spots: a new tool for tuberculosis treatment optimization. Curr Pharm Des 17(27):2931\u20132939. https:\/\/doi.org\/10.2174\/138161211797470174","journal-title":"Curr Pharm Des"},{"issue":"11","key":"3749_CR127","doi-asserted-by":"publisher","first-page":"5758","DOI":"10.1128\/AAC.01054-12","volume":"56","author":"DH Vu","year":"2012","unstructured":"Vu DH, Bolhuis MS, Koster RA, Greijdanus B, de Lange WC, van Altena R et al (2012) Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother 56(11):5758\u20135763. https:\/\/doi.org\/10.1128\/AAC.01054-12","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"3749_CR128","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1183\/13993003.00040-2016","volume":"47","author":"S Ghimire","year":"2016","unstructured":"Ghimire S, Bolhuis MS, Sturkenboom MG, Akkerman OW, de Lange WC, van der Werf TS, Alffenaar JW (2016) Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics. Eur Respir J 47(6):1867\u20131869. https:\/\/doi.org\/10.1183\/13993003.00040-2016","journal-title":"Eur Respir J"},{"issue":"3","key":"3749_CR129","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/FTD.0b013e31821b793c","volume":"33","author":"AD Pranger","year":"2011","unstructured":"Pranger AD, Kosterink JG, van Altena R, Aarnoutse RE, van der Werf TS, Uges DR et al (2011) Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis. Ther Drug Monit 33(3):350\u2013354. https:\/\/doi.org\/10.1097\/FTD.0b013e31821b793c","journal-title":"Ther Drug Monit"},{"issue":"1","key":"3749_CR130","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/FTD.0b013e3181cc6d6f","volume":"32","author":"JW Alffenaar","year":"2010","unstructured":"Alffenaar JW, Kosterink JG, van Altena R, van der Werf TS, Uges DR, Proost JH (2010) Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Ther Drug Monit 32(1):97\u2013101. https:\/\/doi.org\/10.1097\/FTD.0b013e3181cc6d6f","journal-title":"Ther Drug Monit"},{"issue":"10","key":"3749_CR131","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141002","volume":"10","author":"P Denti","year":"2015","unstructured":"Denti P, Jeremiah K, Chigutsa E, Faurholt-Jepsen D, PrayGod G, Range N et al (2015) Pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in newly diagnosed pulmonary TB patients in Tanzania. PLoS ONE 10(10):e0141002. https:\/\/doi.org\/10.1371\/journal.pone.0141002","journal-title":"PLoS ONE"},{"key":"3749_CR132","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.932686","volume":"13","author":"B Chen","year":"2022","unstructured":"Chen B, Shi HQ, Feng MR, Wang XH, Cao XM, Cai WM (2022) Population pharmacokinetics and pharmacodynamics of isoniazid and its metabolite acetylisoniazid in Chinese population. Front Pharmacol 13:932686. https:\/\/doi.org\/10.3389\/fphar.2022.932686","journal-title":"Front Pharmacol"},{"issue":"2","key":"3749_CR133","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/cid\/cis353","volume":"55","author":"JG Pasipanodya","year":"2012","unstructured":"Pasipanodya JG, Srivastava S, Gumbo T (2012) Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis 55(2):169\u2013177. https:\/\/doi.org\/10.1093\/cid\/cis353","journal-title":"Clin Infect Dis"},{"issue":"4","key":"3749_CR134","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1128\/AAC.05792-11","volume":"56","author":"W Smythe","year":"2012","unstructured":"Smythe W, Khandelwal A, Merle C, Rustomjee R, Gninafon M, Bocar Lo M et al (2012) A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients. Antimicrob Agents Chemother 56(4):2091\u20132098. https:\/\/doi.org\/10.1128\/AAC.05792-11","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"3749_CR135","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1093\/cid\/cir184","volume":"52","author":"J van Ingen","year":"2011","unstructured":"van Ingen J, Aarnoutse RE, Donald PR, Diacon AH, Dawson R, Plemper van Balen G et al (2011) Why do we use 600 mg of rifampicin in tuberculosis treatment? Clin Infect Dis 52(9):e194\u2013e199. https:\/\/doi.org\/10.1093\/cid\/cir184","journal-title":"Clin Infect Dis"},{"issue":"8","key":"3749_CR136","doi-asserted-by":"publisher","first-page":"e00038","DOI":"10.1128\/AAC.00038-17","volume":"61","author":"CA Peloquin","year":"2017","unstructured":"Peloquin CA, Vel\u00e1squez GE, Lecca L, Calder\u00f3n RI, Coit J, Milstein M et al (2017) Pharmacokinetic evidence from the HIRIF trial to support increased doses of rifampin for tuberculosis. Antimicrob Agents Chemother 61(8):e00038-e117. https:\/\/doi.org\/10.1128\/AAC.00038-17","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"3749_CR137","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1164\/rccm.201712-2524OC","volume":"198","author":"GE Vel\u00e1squez","year":"2018","unstructured":"Vel\u00e1squez GE, Brooks MB, Coit JM, Pertinez H, Vargas V\u00e1squez D, S\u00e1nchez Garavito E et al (2018) Efficacy and safety of high-dose rifampin in pulmonary tuberculosis. A randomized controlled 341 trial. Am J Respir Crit Care Med 198(5):657\u201366. https:\/\/doi.org\/10.1164\/rccm.201712-2524OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"3749_CR138","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0213718","volume":"14","author":"C Seijger","year":"2019","unstructured":"Seijger C, Hoefsloot W, Bergsma-de Guchteneire I, Te Brake L, van Ingen J, Kuipers S et al (2019) High-dose rifampicin in tuberculosis: experiences from a Dutch tuberculosis centre. PLoS ONE 14(3):e0213718. https:\/\/doi.org\/10.1371\/journal.pone.0213718","journal-title":"PLoS ONE"},{"key":"3749_CR139","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/S2213-2600(18)30044-4","volume":"4","author":"C Magis-Escurra","year":"2018","unstructured":"Magis-Escurra C, Anthony RM, van der Zanden AGM, van Soolingen D, Alffenaar JC (2018) Pound foolish and penny wise-when will dosing of rifampicin be optimised? Lancet Respir Med 4:e11\u2013e12. https:\/\/doi.org\/10.1016\/S2213-2600(18)30044-4","journal-title":"Lancet Respir Med"},{"issue":"9","key":"3749_CR140","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40262-019-00764-2","volume":"58","author":"AA Abulfathi","year":"2019","unstructured":"Abulfathi AA, Decloedt EH, Svensson EM, Diacon AH, Donald P, Reuter H (2019) Clinical pharmacokinetics and pharmacodynamics of rifampicin in human tuberculosis. Clin Pharmacokinet 58(9):1103\u20131129. https:\/\/doi.org\/10.1007\/s40262-019-00764-2","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"3749_CR141","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1128\/AAC.00756-15","volume":"59","author":"MG Sturkenboom","year":"2015","unstructured":"Sturkenboom MG, Mulder LW, de Jager A, van Altena R, Aarnoutse RE, de Lange WC et al (2015) Pharmacokinetic modeling and optimal sampling strategies for therapeutic drug monitoring of rifampin in patients with tuberculosis. Antimicrob Agents Chemother 59(8):4907\u20134913. https:\/\/doi.org\/10.1128\/AAC.00756-15","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"3749_CR142","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1093\/jac\/dkw024","volume":"71","author":"Y Crabol","year":"2016","unstructured":"Crabol Y, Catherinot E, Veziris N, Jullien V, Lortholary O (2016) Rifabutin: where do we stand in 2016? J Antimicrob Chemother 71(7):1759\u20131771. https:\/\/doi.org\/10.1093\/jac\/dkw024","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"3749_CR143","doi-asserted-by":"publisher","first-page":"6366","DOI":"10.1128\/AAC.01124-13","volume":"57","author":"B Williamson","year":"2013","unstructured":"Williamson B, Dooley KE, Zhang Y, Back DJ, Owen A (2013) Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. Antimicrob Agents Chemother 57(12):6366\u20136369. https:\/\/doi.org\/10.1128\/AAC.01124-13","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"3749_CR144","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/clpt.2011.323","volume":"91","author":"KE Dooley","year":"2012","unstructured":"Dooley KE, Bliven-Sizemore EE, Weiner M, Lu Y, Nuermberger EL, Hubbard WC et al (2012) Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Clin Pharmacol Ther 91(5):881\u2013888. https:\/\/doi.org\/10.1038\/clpt.2011.323","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"3749_CR145","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1080\/17512433.2017.1366311","volume":"10","author":"O Alfarisi","year":"2017","unstructured":"Alfarisi O, Alghamdi WA, Al-Shaer MH, Dooley KE, Peloquin CA (2017) Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis? Expert Rev Clin Pharmacol 10(10):1027\u20131036. https:\/\/doi.org\/10.1080\/17512433.2017.1366311","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"3749_CR146","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/jac\/dkt483","volume":"69","author":"M Weiner","year":"2014","unstructured":"Weiner M, Egelund EF, Engle M, Kiser M, Prihoda TJ, Gelfond JA et al (2014) Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. J Antimicrob Chemother 69(4):1079\u20131085. https:\/\/doi.org\/10.1093\/jac\/dkt483","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"3749_CR147","first-page":"1360","volume":"8","author":"M Zhu","year":"2004","unstructured":"Zhu M, Burman WJ, Starke JR, Stambaugh JJ, Steiner P, Bulpitt AE et al (2004) Pharmacokinetics of ethambutol in children and adults with tuberculosis. Int J Tuberc Lung Dis 8(11):1360\u20131367","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"3749_CR148","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ijantimicag.2014.04.019","volume":"44","author":"C Magis-Escurra","year":"2014","unstructured":"Magis-Escurra C, Later-Nijland HM, Alffenaar JW, Broeders J, Burger DM, van Crevel R et al (2014) Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin. Int J Antimicrob Agents 44(3):229\u2013234. https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.04.019","journal-title":"Int J Antimicrob Agents"},{"key":"3749_CR149","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1164\/arrd.1986.134.5.1052","volume":"134","author":"AJ Crowle","year":"1986","unstructured":"Crowle AJ, Sharbaro JA, May KH (1986) Inhibition by pyrazinamide of tubercle bacilli within cultured human macrophages. Am Rev Respir Dis 134:1052\u20131055. https:\/\/doi.org\/10.1164\/arrd.1986.134.5.1052","journal-title":"Am Rev Respir Dis"},{"issue":"4","key":"3749_CR150","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1155\/2011\/307150","volume":"18","author":"A Babalik","year":"2011","unstructured":"Babalik A, Babalik A, Mannix S, Francis D, Menzies D (2011) Therapeutic drug monitoring in the treatment of active tuberculosis. Can Respir J 18(4):225\u2013229. https:\/\/doi.org\/10.1155\/2011\/307150","journal-title":"Can Respir J"},{"issue":"6","key":"3749_CR151","doi-asserted-by":"publisher","first-page":"819","DOI":"10.5588\/ijtld.15.0803","volume":"20","author":"L Mota","year":"2016","unstructured":"Mota L, Al-Efraij K, Campbell JR, Cook VJ, Marra F, Johnston J (2016) Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review and meta-analysis. Int J Tuberc Lung Dis 20(6):819\u2013826. https:\/\/doi.org\/10.5588\/ijtld.15.0803","journal-title":"Int J Tuberc Lung Dis"},{"issue":"11","key":"3749_CR152","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s40262-019-00763-3","volume":"58","author":"AMI Saktiawati","year":"2019","unstructured":"Saktiawati AMI, Harkema M, Setyawan A, Subronto YW, Sumardi SY et al (2019) Optimal sampling strategies for therapeutic drug monitoring of first-line tuberculosis drugs in patients with tuberculosis. Clin Pharmacokinet 58(11):1445\u20131454. https:\/\/doi.org\/10.1007\/s40262-019-00763-3","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"3749_CR153","doi-asserted-by":"publisher","first-page":"4605","DOI":"10.1128\/AAC.00177-10","volume":"54","author":"F Pea","year":"2010","unstructured":"Pea F, Furlanut M, Cojutti P, Cristini F, Zamparini E, Franceschi L, Viale P (2010) Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother 54(11):4605\u20134610. https:\/\/doi.org\/10.1128\/AAC.00177-10","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"3749_CR154","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40268-015-0117-5","volume":"16","author":"NR Srinivas","year":"2016","unstructured":"Srinivas NR, Syed M (2016) Applicability of a single time point strategy for the prediction of area under the concentration curve of linezolid in patients: superiority of Ctrough- over Cmax-derived linear regression models. Drugs RD 16(1):69\u201379. https:\/\/doi.org\/10.1007\/s40268-015-0117-5","journal-title":"Drugs RD"},{"issue":"4","key":"3749_CR155","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1183\/09031936.00176610","volume":"38","author":"AD Pranger","year":"2011","unstructured":"Pranger AD, van Altena R, Aarnoutse RE, van Soolingen D, Uges DR, Kosterink JG et al (2011) Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. Eur Respir J 38(4):888\u2013894. https:\/\/doi.org\/10.1183\/09031936.00176610","journal-title":"Eur Respir J"},{"issue":"2","key":"3749_CR156","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01829-21","volume":"66","author":"VB Vogensen","year":"2022","unstructured":"Vogensen VB, Bolhuis MS, Sturkenboom MGG, van der Werf TS, de Lange WCM, Anthony RM et al (2022) Clinical relevance of rifampicin-moxifloxacin interaction in isoniazid-resistant\/intolerant tuberculosis patients. Antimicrob Agents Chemother 66(2):e0182921. https:\/\/doi.org\/10.1128\/AAC.01829-21","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"3749_CR157","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1128\/AAC.01621-06","volume":"51","author":"M Weiner","year":"2007","unstructured":"Weiner M, Burman W, Luo CC, Peloquin CA, Engle M, Goldberg S et al (2007) Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother 51(8):2861\u20132866. https:\/\/doi.org\/10.1128\/AAC.01621-06","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"3749_CR158","doi-asserted-by":"publisher","first-page":"5922","DOI":"10.1128\/AAC.00961-16","volume":"60","author":"S Srivastava","year":"2016","unstructured":"Srivastava S, Modongo C, Siyambalapitiyage Dona CW, Pasipanodya JG, Deshpande D, Gumbo T (2016) Amikacin optimal exposure targets in the hollow-fiber system model of tuberculosis. Antimicrob Agents Chemother 60(10):5922\u20135927. https:\/\/doi.org\/10.1128\/AAC.00961-16","journal-title":"Antimicrob Agents Chemother"},{"key":"3749_CR159","doi-asserted-by":"publisher","unstructured":"Peloquin C (2017) The role of therapeutic drug monitoring in mycobacterial infections. Microbiol Spectr 5(1). https:\/\/doi.org\/10.1128\/microbiolspec.TNMI7-0029-2016","DOI":"10.1128\/microbiolspec.TNMI7-0029-2016"},{"key":"3749_CR160","unstructured":"Guideline for the use of amikacin for drug resistant tuberculosis and nontuberculous mycobacterial infections in Queensland Version 1.0 March 2021. https:\/\/www.health.qld.gov.au\/__data\/assets\/pdf_file\/0023\/1044743\/tb-guideline-amikacin-drug-resistant.pdf (Accessed on 6th November, 2023)"},{"issue":"5707","key":"3749_CR161","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1126\/science.1106753","volume":"307","author":"K Andries","year":"2005","unstructured":"Andries K, Verhasselt P, Guillemont J, G\u00f6hlmann HW, Neefs JM, Winkler H et al (2005) A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307(5707):223\u2013227. https:\/\/doi.org\/10.1126\/science.1106753","journal-title":"Science"},{"key":"3749_CR162","doi-asserted-by":"publisher","unstructured":"Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, et al (2014) TMC207-C208 Study Group Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 371(8):723\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1313865","DOI":"10.1056\/NEJMoa1313865"},{"key":"3749_CR163","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1901814","volume":"382","author":"F Conradie","year":"2020","unstructured":"Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, for the Nix-TB Trial Team et al (2020) Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med 382:893\u2013902. https:\/\/doi.org\/10.1056\/NEJMoa1901814","journal-title":"N Engl J Med"},{"key":"3749_CR164","unstructured":"New treatment for drug-resistant tuberculosis. https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2023\/featured-topics\/new-treatment-tb"},{"key":"3749_CR165","unstructured":"Center for drug evaluaton and research.\u00a0Multidisciplinary review for application number 212862Orig1s000"},{"issue":"4","key":"3749_CR166","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1093\/jac\/dkab505","volume":"77","author":"SE Mudde","year":"2022","unstructured":"Mudde SE, Upton AM, Lenaerts A, Bax HI, De Steenwinkel JEM (2022) Delamanid or pretomanid? A Solomonic judgement! J Antimicrob Chemother 77(4):880\u2013902. https:\/\/doi.org\/10.1093\/jac\/dkab505","journal-title":"J Antimicrob Chemother"},{"key":"3749_CR167","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.tube.2018.04.008","volume":"111","author":"Y Liu","year":"2018","unstructured":"Liu Y, Matsumoto M, Ishida H, Ohguro K, Yoshitake M, Gupta R et al (2018) Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB). Tuberculosis 111:20\u201330. https:\/\/doi.org\/10.1016\/j.tube.2018.04.008","journal-title":"Tuberculosis"},{"issue":"2","key":"3749_CR168","doi-asserted-by":"publisher","first-page":"74","DOI":"10.2165\/00003088-198916020-00002","volume":"16","author":"MR Holdiness","year":"1989","unstructured":"Holdiness MR (1989) (1989) Clinical pharmacokinetics of clofazimine. A review Clin Pharmacokinet 16(2):74\u201385. https:\/\/doi.org\/10.2165\/00003088-198916020-00002","journal-title":"A review Clin Pharmacokinet"},{"key":"3749_CR169","doi-asserted-by":"publisher","first-page":"1100488","DOI":"10.3389\/fphar.2023.1100488","volume":"14","author":"JAM Stadler","year":"2023","unstructured":"Stadler JAM, Maartens G, Meintjes G, Wasserman S (2023) Clofazimine for the treatment of tuberculosis. Front Pharmacol 14:1100488. https:\/\/doi.org\/10.3389\/fphar.2023.1100488","journal-title":"Front Pharmacol"},{"key":"3749_CR170","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.tube.2015.09.007","volume":"97","author":"S Thee","year":"2016","unstructured":"Thee S, Garcia-Prats AJ, Donald PR, Hesseling AC, Schaaf HS (2016) A review of the use of ethionamide and prothionamide in childhood tuberculosis. Tuberculosis (Edinb) 97:126\u201336. https:\/\/doi.org\/10.1016\/j.tube.2015.09.007","journal-title":"Tuberculosis (Edinb)"},{"issue":"1","key":"3749_CR171","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1128\/AAC.00558-10","volume":"55","author":"JB Bruning","year":"2011","unstructured":"Bruning JB, Murillo AC, Chacon O, Barletta RG, Sacchettini JC (2011) Structure of the Mycobacterium tuberculosis D-alanine:D-alanine ligase, a target of the antituberculosis drug D-cycloserine. Antimicrob Agents Chemother 55(1):291\u2013301. https:\/\/doi.org\/10.1128\/AAC.00558-10","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl_3","key":"3749_CR172","doi-asserted-by":"publisher","first-page":"S308","DOI":"10.1093\/cid\/ciy624","volume":"67","author":"D Deshpande","year":"2018","unstructured":"Deshpande D, Alffenaar JC, K\u00f6ser CU, Dheda K, Chapagain ML, Simbar N et al (2018) d-Cycloserine pharmacokinetics\/pharmacodynamics, susceptibility, and dosing implications in multidrug-resistant tuberculosis: A Faustian deal. Clin Infect Dis 67(suppl_3):S308\u2013S316. https:\/\/doi.org\/10.1093\/cid\/ciy624","journal-title":"Clin Infect Dis"},{"issue":"8","key":"3749_CR173","doi-asserted-by":"publisher","first-page":"931","DOI":"10.5588\/ijtld.17.0648","volume":"22","author":"H Zhu","year":"2018","unstructured":"Zhu H, Guo SC, Liu ZQ, Wang B, Fu L, Chu NH et al (2018) Therapeutic drug monitoring of cycloserine and linezolid during anti-tuberculosis treatment in Beijing. China Int J Tuberc Lung Dis 22(8):931\u2013936. https:\/\/doi.org\/10.5588\/ijtld.17.0648","journal-title":"China Int J Tuberc Lung Dis"},{"issue":"5","key":"3749_CR174","doi-asserted-by":"publisher","first-page":"601","DOI":"10.5588\/ijtld.13.0268","volume":"18","author":"WY Hung","year":"2014","unstructured":"Hung WY, Yu MC, Chiang YC, Chang JH, Chiang CY, Chang CC et al (2014) Serum concentrations of cycloserine and outcome of multidrug-resistant tuberculosis in Northern Taiwan. Int J Tuberc Lung Dis 18(5):601\u2013606. https:\/\/doi.org\/10.5588\/ijtld.13.0268","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"3749_CR175","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40264-015-0267-y","volume":"38","author":"G Ramachandran","year":"2015","unstructured":"Ramachandran G, Swaminathan S (2015) Safety and Tolerability Profile of Second-Line Anti-Tuberculosis Medications. Drug Saf 38(3):253\u2013269. https:\/\/doi.org\/10.1007\/s40264-015-0267-y","journal-title":"Drug Saf"},{"key":"3749_CR176","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.ijid.2021.03.001","volume":"105","author":"R Court","year":"2021","unstructured":"Court R, Centner CM, Chirehwa M, Wiesner L, Denti P, de Vries N et al (2021) Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis. Int J Infect Dis 105:688\u2013694. https:\/\/doi.org\/10.1016\/j.ijid.2021.03.001","journal-title":"Int J Infect Dis"},{"issue":"5","key":"3749_CR177","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1378\/chest.120.5.1520","volume":"120","author":"JB Mehta","year":"2001","unstructured":"Mehta JB, Shantaveerapa H, Byrd RP Jr, Morton SE, Fountain F, Roy TM (2001) Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. Chest 120(5):1520\u20131524. https:\/\/doi.org\/10.1378\/chest.120.5.1520","journal-title":"Chest"},{"issue":"6","key":"3749_CR178","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1517\/17425255.2014.895813","volume":"10","author":"J Reynolds","year":"2014","unstructured":"Reynolds J, Heysell SK (2014) Understanding pharmacokinetics to improve tuberculosis treatment outcome. Expert Opin Drug Metab Toxicol 10(6):813\u2013823. https:\/\/doi.org\/10.1517\/17425255.2014.895813","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"3749_CR179","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1093\/jac\/dku345","volume":"70","author":"JG Pasipanodya","year":"2015","unstructured":"Pasipanodya JG, Srivastava S, Gumbo T (2015) Comment on: Clinical significance of 2 h plasma concentrations of first-line antituberculosis drugs: a prospective observational study. J Antimicrob Chemother 70:320\u2013321. https:\/\/doi.org\/10.1093\/jac\/dku345","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"3749_CR180","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1183\/09031936.00177014","volume":"46","author":"RE Aarnoutse","year":"2015","unstructured":"Aarnoutse RE, Sturkenboom MG, Robijns K, Harteveld AR, Greijdanus B, Uges DR, Touw DJ, Alffenaar JW (2015) An interlaboratory quality control programme for the measurement of tuberculosis drugs. Eur Respir J 46(1):268\u2013271. https:\/\/doi.org\/10.1183\/09031936.00177014","journal-title":"Eur Respir J"},{"key":"3749_CR181","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.992354","volume":"13","author":"J Hou","year":"2022","unstructured":"Hou J, Marriott D, Cattaneo D, Stocker S, Stojanova J, Alffenaar J-W, Xiao C, Zhao Y, Gong H, Yan M (2022) Therapeutic drug monitoring practices of anti-infectives: an Asia-wide cross-sectional survey. Front Pharmacol 13:992354. https:\/\/doi.org\/10.3389\/fphar.2022.992354","journal-title":"Front Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03749-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03749-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03749-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T06:06:15Z","timestamp":1728281175000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03749-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,6]]},"references-count":181,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["3749"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03749-8","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,6]]},"assertion":[{"value":"23 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}